<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02000401</url>
  </required_header>
  <id_info>
    <org_study_id>0703-2012-SPRIX</org_study_id>
    <nct_id>NCT02000401</nct_id>
  </id_info>
  <brief_title>Intranasal Ketorolac Tromethamine (Sprix) for Acute Pain of Interstitial Cystitis Flare of Pain</brief_title>
  <official_title>To Evaluate the Efficacy, Tolerability, and Safety of Intranasal Ketorolac Tromethamine (Sprix) as an Option for Acute (up to 5 Days) Pain Management Adult Interstitial Cystitis Patients Experiencing a Flare of Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Citrus Valley Medical Research, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Citrus Valley Medical Research, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intranasal Ketorolac tromethamine has a potential role as a short term pain management tool&#xD;
      for Interstitial Cystitis without the risk and undesirable effects of narcotics.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Scores on the Visual Analog Scale</measure>
    <time_frame>5 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>5 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Interstitial Cystitis</condition>
  <arm_group>
    <arm_group_label>Ketorolac Tromethamine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Ketorolac Tromethamine one 15.75 mg spray in each nostril for a total dose of 31.5 mg which can be repeated every 6-8 hrs. as needed for pain with a maximum daily dose of 126 mg. The treatment may be continued for up to 5 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac Tromethamine</intervention_name>
    <arm_group_label>Ketorolac Tromethamine</arm_group_label>
    <other_name>SPRIX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female Subject must be between the age eighteen (18) years and sixty four (64)&#xD;
&#xD;
          2. Subject must weigh 110lbs (50kg) or greater&#xD;
&#xD;
          3. Willing and able to provide an informed consent&#xD;
&#xD;
          4. Diagnosed with Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS)&#xD;
&#xD;
          5. Symptoms of IC/PBS that are moderate to severe (intermittent or chronic) for ≥ three&#xD;
             (3) months&#xD;
&#xD;
          6. A cystoscopic examination under anesthesia with hydro-distention and photo&#xD;
             documentation will have been performed at time of diagnosis with IC. Bladder biopsies&#xD;
             will have been performed only if carcinoma is suspected. (see exclusion # 5.2.25 -&#xD;
             hydrodistention must be performed greater than four (4) weeks prior to baseline visit)&#xD;
             Note: at investigator discretion subject may included with only operative report&#xD;
&#xD;
          7. At screening subject must have a score ≥ four (4) out of ten (10) On Visual Analogue&#xD;
             Pain Scale (VAS Pain Scale)&#xD;
&#xD;
          8. Subject must have a score on the O'Leary/Sant scale of at least a five (5) on the&#xD;
             symptom index at screening&#xD;
&#xD;
          9. Voids greater than eight (8) in a twenty four (24) hour period&#xD;
&#xD;
         10. Nocturia of at least one (1) time during sleeping period&#xD;
&#xD;
         11. Subject of child-bearing potential must test negative for pregnancy prior to treatment&#xD;
             or provide documentation for having undergone the following: hysterectomy or tubal&#xD;
             ligation. Subjects who are physiologically capable of becoming pregnant must&#xD;
             voluntarily sign a pregnancy waiver included within the informed consent and agree not&#xD;
             to become pregnant for the duration of the study and for thirty (30) days following&#xD;
             the completion of study. If a subject becomes pregnant during the course of this&#xD;
             study, the subject will inform the Principal Investigator within one (1) working day&#xD;
             of learning of the pregnancy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current treatment with or known allergy or sensitivity to all forms of ketorolac&#xD;
             tromethamine, aspirin, other non-steroidal anti-inflammatory drugs (NSAIDs) or&#xD;
             Ethylenediaminetetraacetic acid (EDTA) NOTE: if at time of signing consent a subject&#xD;
             is receiving a non-steroidal inflammatory drug they may washout for seven days prior&#xD;
             to completing the screening visit&#xD;
&#xD;
          2. Subject is currently receiving or having had prior IC/PBS focused therapy on less than&#xD;
             three (3) months stable doses. i.e. oral Pentosan Polysulfate(PPS) (Elmiron®),&#xD;
             Amitriptyline (Elavil®), oxychlorosene (Clorpactin®), dimethyl sulfoxide (RIMSO 50™),&#xD;
             heparin or antihistamine NOTE: Antihistamine is allowable as added treatment during&#xD;
             course of study if for treatment of diagnosed nasal/seasonal/environmental allergy&#xD;
             (i.e treatment other than IC) , If a subject is receiving intravesical instillations&#xD;
             of any kind at least a two day washout must be adhered to before screening is&#xD;
             performed. The subject must abstain from any intravesical instillation during the&#xD;
             study.&#xD;
&#xD;
          3. Current use of TENS (Transcutaneous Electrical Nerve Stimulation) or Interstim unit&#xD;
&#xD;
          4. Clinically significant urinary tract infection (UTI) NOTE: dipstick urinalysis is done&#xD;
             at screening urine culture will be performed if indicated by results of dipstick&#xD;
             urinalysis at screening&#xD;
&#xD;
          5. As needed Use of narcotics/opiate within one (1) week prior to the screening visit and&#xD;
             entire study participation by self-reporting (Note: once subject has qualified they&#xD;
             will be given the option of rescue medication for pain not relieved by the study&#xD;
             medication)&#xD;
&#xD;
          6. Use of illegal drugs by self-reporting&#xD;
&#xD;
          7. History of drug or alcohol abuse within five (5) years of screening visit&#xD;
&#xD;
          8. History of suicide attempt or suicidal thoughts by self-reporting within five (5)&#xD;
             years of screening visit&#xD;
&#xD;
          9. Any active co-morbid pelvic diagnosis (i.e. endometriosis, Irritable Bowel Syndrome,&#xD;
             etc.) for which the subject is unable to distinguish between IC/PBS pain and pain from&#xD;
             any other condition as determined by the investigator&#xD;
&#xD;
         10. A diagnosis of a severe neuro-psychiatric disease&#xD;
&#xD;
         11. Subject demonstrates an absence of nocturia&#xD;
&#xD;
         12. Subject's frequency of urination is equal to or less than eight (8) times in a twenty&#xD;
             four (24) hour period.&#xD;
&#xD;
         13. Subject's symptoms relieved by antimicrobials, urinary antiseptics, anticholinergics,&#xD;
             or antispasmodics.&#xD;
&#xD;
         14. Subject has recurrent bladder or lower urethral calculi (recurrent is defined as &gt; to&#xD;
             3 times in a 12 month period)&#xD;
&#xD;
         15. Subject has active genital herpes with a (3) three month period of the screening visit&#xD;
&#xD;
         16. Subject has uterine, cervical, vaginal, or urethral cancer&#xD;
&#xD;
         17. Subject has been administered cyclophosphamide or any agent that causes chemical&#xD;
             cystitis&#xD;
&#xD;
         18. Subject has tubercular cystitis&#xD;
&#xD;
         19. Subject has radiation cystitis&#xD;
&#xD;
         20. Subject has benign or malignant bladder tumor&#xD;
&#xD;
         21. Subject has a positive pathologic vaginal culture within three (3) months of the&#xD;
             screening visit&#xD;
&#xD;
         22. Subject has evidence of vesicle ureteral reflux or urethral diverticula&#xD;
&#xD;
         23. Subject has neurogenic bladder dysfunction&#xD;
&#xD;
         24. Subject has a prior urinary diversion&#xD;
&#xD;
         25. Subject who is currently receiving investigational drug(s) or participated in a&#xD;
             clinical trial involving investigational drug(s) within thirty (30) day of the&#xD;
             screening visit&#xD;
&#xD;
         26. Subject who is pregnant or lactating&#xD;
&#xD;
         27. Subject with history of hydro-distention within four (4) weeks of baseline visit&#xD;
&#xD;
         28. Subject with history of clinically significant cardiovascular disease such as:&#xD;
             (chronic stable angina being currently treated with long acting nitrates, chronic&#xD;
             stable angina require treatment with short acting nitrates with 90 days of visit 1,&#xD;
             angina occurring during sexual intercourse in the last six months, unstable angina&#xD;
             within six months of visit 1&#xD;
&#xD;
         29. Resting, sitting blood pressure (BP) &gt; 160mm Hg in systolic pressure or &gt; 100mm Hg is&#xD;
             diastolic pressure at screening. If a patient is found to have untreated significant&#xD;
             hypertension at screening and antihypertensive treatment is initiated, assessment for&#xD;
             study eligibility should be deferred until BP and antihypertensive medication have&#xD;
             been stable for at least one month. For patients with previously diagnosed&#xD;
             hypertension, antihypertensive medications must be stable for at least one month prior&#xD;
             to screening.&#xD;
&#xD;
         30. Subject over sixty four (64) years of age&#xD;
&#xD;
         31. Subject who weighs less than 110lbs (50kg)&#xD;
&#xD;
         32. Subject with history of any clinically significant blood chemistry, renal function or&#xD;
             liver abnormality defined as + two (2X) normal values&#xD;
&#xD;
         33. Subject who has history of a bleeding problem or low platelet count&#xD;
&#xD;
         34. Known or suspected cerebrovascular bleeding, hemorrhagic diathesis or incomplete&#xD;
             hemostasis, and those at high risk of bleeding, have history of a bleeding problem or&#xD;
             low platelet count or coagulation disorder or are on therapy that affects homeostasis&#xD;
&#xD;
         35. Active peptic ulcer disease, recent GI bleeding or perforation, or a history of peptic&#xD;
             ulcers or GI bleeding&#xD;
&#xD;
         36. History of asthma, urticaria or other allergic-type reaction after taking aspirin or&#xD;
             other non- steroidal inflammatory drugs (NASIDs)&#xD;
&#xD;
         37. Subject who has history of swelling of face, mouth, tongue, lips, gums, neck, or&#xD;
             throat (angioedema) or with cardiac decompensation or similar conditions&#xD;
&#xD;
         38. Major surgery scheduled within 3 weeks or screening and for entire participation of&#xD;
             study&#xD;
&#xD;
         39. Current exfoliative dermatitis, Stevens-Johnson syndrome or toxic epidermal necrolysis&#xD;
&#xD;
         40. Any condition in the opinion of the investigator that makes the subject unsuitable for&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward L Davis, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Citrus Valley Medical Research, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Citrus Valley Medical Research, Inc</name>
      <address>
        <city>Glendora</city>
        <state>California</state>
        <zip>91741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <study_first_submitted>November 19, 2013</study_first_submitted>
  <study_first_submitted_qc>December 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2013</study_first_posted>
  <last_update_submitted>December 3, 2013</last_update_submitted>
  <last_update_submitted_qc>December 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystitis</mesh_term>
    <mesh_term>Cystitis, Interstitial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

